Eupraxia Pharmaceuticals, Inc. (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc. has formed a Gastrointestinal Clinical Advisory Board to guide the development of their treatment for eosinophilic esophagitis, EP-104GI, which is currently undergoing Phase 1b/2a trials. The new board, boasting GI experts, aligns with the company’s strides in addressing this rare disease’s therapeutic needs, utilizing their proprietary DiffuSphere technology for enhanced drug delivery. The company believes EP-104GI shows promise in meeting the significant unmet medical need of the EoE patient population.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
